pan-PRL inhibitor

A pan-PRL inhibitor is a therapeutic agent designed to inhibit all three isoforms of the Protein Tyrosine Phosphatase 4A (PTP4A) family, commonly known as Phosphatase of Regenerating Liver (PRL-1, PRL-2, and PRL-3). These oncogenic phosphatases are frequently overexpressed in various malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and metastatic solid tumors, where they promote cell proliferation, migration, and survival. By targeting all three isoforms, pan-PRL inhibitors aim to overcome functional redundancy among the PRL proteins. In preclinical zebrafish models of T-ALL, pan-PRL inhibition has demonstrated the ability to significantly delay leukemia onset and progression, suggesting that these phosphatases are critical drivers of leukemogenesis and potential targets for molecularly targeted therapy. JMS-053 is a prominent small molecule example of this class, developed to block the phosphatase activity of the entire PRL family.

Other names

PRL inhibitorpan-PTP4A inhibitorpan-PTP-4A inhibitorpan-PTP 4A inhibitor